Vividion Therapeutics starts Phase I clinical trial in advanced solid tumors with KEAP1 activator
- Details
- Category: Bayer
Vividion Therapeutics, Inc. (Vividion), announced today that it has initiated dosing of patients in a Phase I oncology clinical trial of its investigational oral Kelch-like ECH Associated Protein 1 (KEAP1) activator, VVD-130037. Vividion is a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, and a wholly owned and independently operated subsidiary of Bayer AG.
GSK and Save the Children renew award-winning partnership, with focus on 'zero dose' children who have never received a vaccine
- Details
- Category: GlaxoSmithKline
GSK and Save the Children have announced today that they are renewing their award-winning partnership for a further five years. GSK will invest £15 million in the partnership with Save the Children and they will work together to increase child vaccination rates, with a focus on reducing the number of 'zero dose' children in Ethiopia and Nigeria.
Roche's Alecensa delivers unprecedented Phase III results for people with ALK-positive early-stage lung cancer
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the Phase III ALINA study evaluating Alecensa® (alectinib), compared with platinum-based chemotherapy, met its primary endpoint of disease-free survival (DFS) at a prespecified interim analysis. Alecensa demonstrated a statistically significant and clinically meaningful improvement in DFS as adjuvant therapy in people with completely resected stage IB (tumour ≥4cm) to IIIA (UICC/AJCC 7th edition) anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
BlueRock's Phase I study with bemdaneprocel in patients with Parkinson's disease meets primary endpoint
- Details
- Category: Bayer
Bayer AG and BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned independently operated subsidiary of Bayer AG, announced today details of the positive data from the Phase I clinical trial for bemdaneprocel (BRT-DA01), a stem cell derived investigational therapy for treating Parkinson's disease. The data were presented at the International Congress of Parkinson's Disease and Movement Disorders® in Copenhagen, Denmark.
Novartis completes acquisition of Chinook Therapeutics
- Details
- Category: Novartis
Novartis announced that it has completed its acquisition of Chinook Therapeutics, Inc., a Seattle, WA, based biopharmaceutical company focused on the discovery, development, and commercialization of precision medicines for kidney diseases, in a transaction valued at up to USD 3.5 billion.
U.S. FDA Approves ABRYSVO™, Pfizer's vaccine for the prevention of respiratory syncytial virus (RSV) in infants through active immunization of pregnant individuals 32-36 weeks of gestational age
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO™ (Respiratory Syncytial Virus Vaccine), the company's bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of LRTD and severe LRTD caused by RSV in infants from birth up to six months of age by active immunization of pregnant individuals at 32 through 36 weeks gestational age.
Mahana Therapeutics signs agreement with Consumer Health division of Bayer to commercialize digital therapeutics
- Details
- Category: Bayer
Mahana Therapeutics, a leading provider of prescription digital therapeutics, announced today that the company has entered into a multi-million-dollar distribution and marketing partnership with the Consumer Health division of Bayer to commercialize digital therapeutics. Earlier this year, Bayer announced the launch of a new business unit focused on delivering new digitally enabled precision health products to market.
More Pharma News ...
- AbbVie announces European Commission approval of AQUIPTA® (atogepant) for the preventive treatment of migraine in adults
- Pfizer's ELREXFIO™ receives U.S. FDA accelerated approval for relapsed or refractory multiple myeloma
- Aflibercept 8 mg first to achieve sustained vision gains with more than 70% of patients extended to intervals between 16 and 24 weeks in wet age-related macular degeneration at two years
- Bill & Melinda Gates Foundation, Children's Investment Fund Foundation, Pfizer and Becton, Dickinson & Company expand partnership for greater access to injectable contraceptive for women in low- and lower-middle-income countries
- New research published in Science highlights potential of a naturally occurring bacterium to help eradicate malaria
- AI drives new era of target identification and drug design
- Alexion, AstraZeneca Rare Disease, enters agreement with Pfizer to acquire a portfolio of preclinical rare disease gene therapies